Randomized placebo controlled clinical trial of an enteric coated micro‐pelleted formulation of a pancreatic enzyme supplement in dogs with exocrine pancreatic insufficiency

摘要

Background Pancreatic enzyme supplements for the treatment of exocrine pancreatic insufficiency (EPI) in dogs can be uncoated or enteric coated. Enteric coated supplements might be advantageous. Hypothesis/Objectives Enteric coated enzyme supplements are superior to uncoated supplements in dogs with clinical EPI. Animals Eleven dogs with naturally occurring EPI that were apparently free from other diseases. Methods Randomized, blinded, controlled cross‐over clinical trial comparing a novel micro‐encapsulated enteric coated enzyme supplement to a commercially available uncoated product in dogs with clinical EPI. Search of serum canine serum trypsin‐like immunoreactivity concentration ≤?2.5 μg/L in the Gastrointestinal Laboratory database was used to identify dogs with EPI. Results There was no difference ?4.46% (95% CI: ?7.97%‐–0.96%; P =?.15) in the % acid hydrolysis fecal fat (primary outcome) between the enteric coated formulation (median: 11.8%; range 6.4%‐17.0%) and the uncoated pancreatic enzyme replacement product (median: 17.5%; range: 5.2%‐24.9%) in the 11 dogs that completed the study. Other variables did not differ between treatments. Conclusions and Clinical Importance This study, which had low statistical power, did not detect a difference between formulations.